Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Fineline Cube Mar 31, 2026
Company Drug

Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway

Fineline Cube Mar 31, 2026
Company

Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025

Fineline Cube Aug 19, 2025

China-based Sino Biopharmaceutical Limited (HKG: 1177) announced its financial results for the first half of 2025....

Company Drug

Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial

Fineline Cube Aug 19, 2025

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that it has received approval from...

Company Drug

Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval

Fineline Cube Aug 19, 2025

Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis,...

Company Digital

RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug

Fineline Cube Aug 19, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an agreement with Santen China, a...

Company Medical Device

MicroPort CardioFlow’s Alwide Plus Wins EU CE Mark for Heart Valve Procedures

Fineline Cube Aug 19, 2025

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), based in China, announced that its independently...

Company Drug

Mabwell’s Innovative CDH17-Targeted ADC 7MW4911 Receives FDA Clinical Trial Approval

Fineline Cube Aug 19, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate...

Company Drug

Hengrui Pharma’s Hetrombopag Olamine Accepted by NMPA for Chemotherapy-Induced Thrombocytopenia

Fineline Cube Aug 19, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the National Medical Products...

Company

WuXi XDC Reports Strong H1 2025 Growth With 62.2% Revenue Increase

Fineline Cube Aug 19, 2025

China-based WuXi XDC Cayman Inc. (HKG: 2268), a leading global Contract Research, Development, and Manufacturing...

Company Deals Drug

Genentech to End $2B Collaboration With Adaptive Biotechnologies on T-Cell Therapies

Fineline Cube Aug 19, 2025

Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), will terminate its strategic...

Company Deals

Henlius Partners with GeneQuantum on HER2-Targeted ADC GQ1005 Development

Fineline Cube Aug 19, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic collaboration with China-based GeneQuantum Healthcare. The...

Company Medical Device

Acotec Scientific’s Micro-Guidewire Receives Beijing Medical Products Administration Approval

Fineline Cube Aug 19, 2025

China-based Acotec Scientific Holdings Limited (HKG: 6669) announced that its micro-guidewire has received registration approval...

Company Deals

Skyhawk Therapeutics Collaborates with Merck on RNA-Targeting Small Molecules for Neurological Diseases

Fineline Cube Aug 19, 2025

Skyhawk Therapeutics, Inc. announced on August 18, 2025, a strategic research collaboration with Merck KGaA...

Company Drug

Sichuan Biokin’s Iza-Bren Granted FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Aug 19, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC), izalontamab...

Company Drug

Ascentage Pharma’s Lisaftoclax Gains FDA and EMA Clearance for Global Phase III Trial

Fineline Cube Aug 18, 2025

Ascentage Pharma Group International (HKG: 6855) announced that it has received clearance from the U.S....

Company Drug

Novo Nordisk’s Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis

Fineline Cube Aug 18, 2025

Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced on August 15, 2025, that its...

Company Drug

Livzon Announces NMPA Acceptance of JP-1366 Tablets Application for Reflux Esophagitis

Fineline Cube Aug 18, 2025

Livzon Pharmaceutical Group Inc. (HKG: 1513) announced that the drug registration application for its JP-1366...

Company Drug

iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy

Fineline Cube Aug 18, 2025

China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has...

Company Drug

Ab&B Bio-Tech’s RSV Vaccine Gains IND Approval in China and the U.S.

Fineline Cube Aug 18, 2025

China-based Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that its self-developed investigational new drug...

Company Drug

Haisco’s HSK39297 Gains NMPA Approval for AMD and gMG Trials

Fineline Cube Aug 18, 2025

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the National Medical Products Administration (NMPA)...

Company Drug

FDA Accelerates Approval of Dordaviprone for H3 K27M-Mutant Diffuse Midline Glioma

Fineline Cube Aug 18, 2025

The U.S. Food and Drug Administration (FDA) granted accelerated approval on August 6, 2025, to...

Posts pagination

1 … 91 92 93 … 643

Recent updates

  • Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership
  • AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations
  • Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety
  • NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma
  • Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Medical Device

Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety

Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.